Notice of the Extraordinary General Meeting of Cell Impact AB (publ)

The shareholders of Cell Impact AB (publ), reg. no. 556576-6655, are hereby invited to participate in the Extraordinary General Meeting to be held on Tuesday 8 December 2026 at 10.30 hours (CET) at the premises of Wåhlin Advokater AB, Nybrogatan 39 in Stockholm, Sweden. Registration starts at 10.00 hours (CET).

Registration and notification

A shareholder who wishes to participate in the Extraordinary General Meeting in person or by proxy:

If a shareholder is represented by proxy, a written and dated proxy for the representative must be issued. The proxy, together with a registration certificate or corresponding authorisation documents for shareholders who are legal entities, should be sent to the company at the above address before the meeting. A proxy form is available on the company’s website www.cellimpact.com.

To be entitled to participate in the meeting, a shareholder whose shares are held in the name of a nominee must, in addition to providing notification of participation, register its shares in its own name so that the shareholder is recorded in the share register relating to the circumstances on 30 November 2026. Such registration may be temporary, so-called voting right registration, and is requested by the nominee in accordance with the nominee’s procedures and in such time in advance as the nominee determines. Voting right registrations completed by the nominee no later than 2 December 2026 are taken into account when preparing the share register.

The Board of Directors proposes that lawyer Anna Klevbo is elected as Chairman of the Extraordinary General Meeting.

In order to enable future decisions on the agenda, the Board of Directors proposes that the meeting resolves to amend the Articles of Association as follows.

The CEO, or the person appointed by the Board of Directors, shall be authorised to make such minor amendments to the meeting’s resolutions as may be required in connection with registration with the Swedish Companies Registration Office and Euroclear Nordics AB or for other administrative reasons.

The resolution is conditional on the meeting resolving in accordance with the Board of Directors’ proposals under section 8 on the agenda.

The Board of Directors assesses that the company’s current capital structure limits the company’s financial flexibility. To increase the company’s scope for action, the Board of Directors therefore proposes that the meeting resolves to reduce the share capital as follows.

The Board of Directors proposes that the general meeting authorises the Board of Directors to decide upon issues of shares, warrants and/or convertibles until the next annual general meeting and within the limits of the Articles of Association, on one or more occasions, with or without deviation from the shareholders’ preferential rights. Issues may be made against cash payment, issue in kind and/or set-off, or otherwise be combined with conditions. If the Board of Directors decides on a share issue with deviation from the shareholders’ preferential rights, the issue shall be carried out on market terms.

Furthermore, the Board of Directors proposes that the Board of Directors, or the person appointed by the Board of Directors, shall have the right to make minor changes to the general meeting’s decision which may be required in connection with registration with the Swedish Companies Registration Office or for other administrative reasons.

A decision in accordance with sections 7–9 on the agenda requires that it is supported by shareholders representing at least two thirds of both the votes cast and the shares represented at the meeting.

The proposals for decisions in the notice are complete. Proxy forms and other documents in accordance with the Swedish Companies Act will be available at the company’s office at Källmossvägen 7 A, 691 52 Karlskoga, Sweden, and on the company’s website www.cellimpact.com no later than three weeks prior to the meeting. The documents will also be sent by post to shareholders who so request and state their postal address.

Shareholders in the company are entitled to information at the meeting about circumstances that may affect the assessment of an item on the agenda in accordance with Chapter 7, Sections 32 and 57 of the Swedish Companies Act.

At the time of the notice, the total number of shares and votes in the company amounts to 1,326,965,692.

For information on how your personal data is processed in connection with the meeting, see the integrity policy that is available on Euroclear’s website: Integrity policy for general meetings.

This is an unofficial translation of the original Swedish notice to the Extraordinary General Meeting. In the event of any discrepancy between the versions, the Swedish version shall prevail.

November 2026

Cell Impact AB (publ)
The Board of Directors

About Cell Impact
Cell Impact AB (publ) is a global supplier of advanced flow plates to fuel cell and electrolyzer manufacturers. The company has developed and patented a unique method for high velocity forming, Cell Impact Forming™ which is significantly more scalable and cost-efficient compared to conventional forming methods. Cell Impact Forming is an environmentally friendly forming technology that consumes no water and very little electrical power. The Cell Impact share is listed on Nasdaq First North Growth Market and Mangold Fondkommission AB is the company’s Certified Advisor (CA).

For more information, please contact:
Daniel Vallin
CEO and IR contact, Cell Impact AB
+46 730-68 66 20 or daniel.vallin@cellimpact.com

Läs mer på Cision